Gerald Sokol Net Worth

Gerald Sokol biography

Gerald H. Sokol M.D. serves as Independent Director of the Company. He has been a member of our Board since March 2015. He also serves on our Medical Advisory Board and as chairman of our Science Development Committee. Dr. Sokol attained his medical degree from Indiana University’s Combined Degree Program in Experimental Medicine together with a Master’s Degree in Pharmacology. He interned in medicine at Temple University and attended the U.S. Public Health Service Hospital in affiliation with the National Cancer Institute, Johns Hopkins and the University of Maryland completing training in internal medicine. He then completed training at the Massachusetts General Hospital, Harvard Medical School in Radiation Oncology, Medical Oncology and Clinical Pharmacology, attaining Board Certifications in Internal Medicine, Medical Oncology, Radiation Oncology, Clinical Pharmacology, and later Quality Assurance and Utilization Review. He also is certified in Skin Cancer Medicine from the University of Queensland. Dr. Sokol has been Chief of Radiation Oncology at the University of South Florida’s Tampa General Hospital and has built or contributed to building over ten cancer centers. He is a board member and partner of Florida Cancer Specialists and Research Institute. Dr. Sokol is a decorated retired Captain in the US Navy and served as a Commanding Officer at the Uniformed Services University. Dr. Sokol currently holds professorships in Medicine and Pharmacology at that institution. While maintaining a medical practice, Dr. Sokol served on the review staff of the FDA for over 27 years as a senior regulatory scientist and officer, composing over 300 white papers, IND and NDA reviews and opinion papers. Dr. Sokol has authored or coauthored over 100 books, book chapters, abstracts and papers on a multitude of clinical issues. He is a lifetime fellow and board member of the American Cancer Society and a fellow of the American College of Clinical Pharmacology.

What is the salary of Gerald Sokol?

As the Independent Director of Tyme Technologies Inc, the total compensation of Gerald Sokol at Tyme Technologies Inc is $102,360. There are 9 executives at Tyme Technologies Inc getting paid more, with James Biehl having the highest compensation of $1,500,980.

How old is Gerald Sokol?

Gerald Sokol is 77, he's been the Independent Director of Tyme Technologies Inc since 2015. There are no older and 18 younger executives at Tyme Technologies Inc.

What's Gerald Sokol's mailing address?

Gerald's mailing address filed with the SEC is C/O TYME TECHNOLOGIES, INC., 1 PLUCKEMIN WAY - SUITE 103, BEDMINSTER, NJ, 07921.

Insiders trading at Tyme Technologies Inc

Over the last 7 years, insiders at Tyme Technologies Inc have traded over $11,656,990 worth of Tyme Technologies Inc stock and bought 384,831 units worth $412,502 . The most active insiders traders include Steve Hoffman, Michael Demurjian y Douglas A Michels. On average, Tyme Technologies Inc executives and independent directors trade stock every 8 days with the average trade being worth of $15,104. The most recent stock trade was executed by Michael Demurjian on 6 September 2022, trading 160,000 units of TYME stock currently worth $40,000.

What does Tyme Technologies Inc do?

Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system.

With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19.

Tyme Technologies Inc executives and stock owners

Tyme Technologies Inc executives and other stock owners filed with the SEC include:

• James Biehl,
  Chief Legal Officer and Corporate Secretary
• Michele Korfin,
  Chief Operating Officer
• Steve Hoffman,
  Chairman of the Board, Chief Executive Officer, Chief Science Officer
• Steven E. Hoffman,
  Co-Founder, Chairman & Chief Science Officer
• James Biehl J.D.,
  Chief Legal Officer & Sec.
• Dr. Jonathan M. Eckard,
  Chief Bus. Officer
• Richard Cunningham,
  CEO & Director
• David Carberry,
  Independent Director
• Donald Degolyer,
  Independent Director
• Gerald Sokol,
  Independent Director
• Timothy Tyson,
  Independent Director
• Douglas Michels,
  Independent Director
• Paul Sturman,
  Independent Director
• Jonathan Eckard,
  Chief Business Officer
• Giuseppe Del Priore,
  Chief Medical Officer
• Barbara Galaini,
  Principal Financial Officer, Principal Accounting Officer, Corporate Controller
• Frank L. Porfido,
  Chief Financial Officer
• Dr. Jan Marie-Albert Van Tornout M.D., M.Sc.,
  Acting Chief Medical Officer
• Dr. John M. Rothman,
  Exec. VP of Product Devel.
• John Zucaro P.E.,
  Sr. VP of CMC
• Tommy G Thompson,
  Director
• Christine D. Baker,
  Director
• John M. Rothman,
  EVP, Product Development
• Michael Demurjian,
  10% owner
• Ben R Taylor,
  President, CFO
• Tornout Jan M Van,
  Acting Chief Medical Officer
• Christopher F Brown,
  10% owner
• Frank L. Porfido,
  Chief Financial Officer
• Richard Anthony Cunningham,,
  Chief Executive Officer